Gyre Therapeutics (GYRE) Loans and Notes Receivables (2022 - 2025)
Gyre Therapeutics (GYRE) has disclosed Loans and Notes Receivables for 4 consecutive years, with $5.6 million as the latest value for Q4 2025.
- Quarterly Loans and Notes Receivables rose 28.93% to $5.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.6 million through Dec 2025, up 28.93% year-over-year, with the annual reading at $5.6 million for FY2025, 28.93% up from the prior year.
- Loans and Notes Receivables for Q4 2025 was $5.6 million at Gyre Therapeutics, up from $693000.0 in the prior quarter.
- The five-year high for Loans and Notes Receivables was $5.6 million in Q4 2025, with the low at $91000.0 in Q3 2024.
- Average Loans and Notes Receivables over 4 years is $1.6 million, with a median of $596000.0 recorded in 2025.
- The sharpest move saw Loans and Notes Receivables plummeted 74.44% in 2023, then surged 1024.16% in 2024.
- Over 4 years, Loans and Notes Receivables stood at $1.5 million in 2022, then tumbled by 74.44% to $389000.0 in 2023, then soared by 1024.16% to $4.4 million in 2024, then increased by 28.93% to $5.6 million in 2025.
- According to Business Quant data, Loans and Notes Receivables over the past three periods came in at $5.6 million, $693000.0, and $499000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.